Crystal structures of the free and inhibited forms of plasmepsin I (PMI) from Plasmodium falciparum

Journal of Structural Biology

Volumn 175, Issue 1, 2011, Pages 73-84

  Bhaumik, Prasenjit ^a   Horimoto, Yasumi ^b   Xiao, Huogen ^b   Miura, Takuya ^c   Hidaka, Koushi ^c   Kiso, Yoshiaki ^c   Wlodawer, Alexander ^a   Yada, Rickey Y ^b   Gustchina, Alla ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF GUELPH   (Canada)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Aspartic protease; Crystal structure; Enzyme inhibition; Malaria; Plasmepsin

Indexed keywords

ALLOPHENYLNORSTATINE DIMETHYLTHIOPROLINE; APOENZYME; ASPARTIC PROTEINASE; KNI 10006; PLASMEPSIN I; PLASMEPSIN INHIBITOR; PROLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; COMPLEX FORMATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME BINDING; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ASPARTIC ACID ENDOPEPTIDASES; BINDING SITES; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HYDROGEN BONDING; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PLASMODIUM FALCIPARUM; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT;

PLASMODIUM FALCIPARUM;

EID: 79956214335     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2011.04.009     Document Type: Article

References (65)

1. Abdel-Rahman H.M., Kimura T., Hidaka K., Kiso A., Nezami A., et al. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases. Biol. Chem. 2004, 385:1035-1039.
2. Asojo O.A., Afonina E., Gulnik S.V., Yu B., Erickson J.W., et al. Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8Å in complex with the inhibitors rs367 and rs370. Acta Crystallogr. 2002, D58:2001-2008.
3. Asojo O.A., Gulnik S.V., Afonina E., Yu B., Ellman J.A., Haque T.S., Silva A.M. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. J. Mol. Biol. 2003, 327:173-181.
4. Bailly E., Jambou R., Savel J., Jaureguiberry G. Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and Pepstatin A (aspartyl protease inhibitor). J. Protozool. 1992, 39:593-599.
5. Banerjee R., Liu J., Beatty W., Pelosof L., Klemba M., Goldberg D.E. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. Natl. Acad. Sci. USA 2002, 99:990-995.
6. Bernstein N.K., Cherney M.M., Loetscher H., Ridley R.G., James M.N. Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from Plasmodium falciparum. Nat. Struct. Biol. 1999, 6:32-37.
7. Bernstein N.K., Cherney M.M., Yowell C.A., Dame J.B., James M.N. Structural insights into the activation of P. vivax plasmepsin. J. Mol. Biol. 2003, 329:505-524.
8. Berry C., Humphreys M.J., Matharu P., Granger R., Horrocks P., et al. A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum. FEBS Lett. 1999, 447:149-154.
9. Bhaumik P., Xiao H., Parr C.L., Kiso Y., Gustchina A., Yada R.Y., Wlodawer A. Crystal structures of the histo-aspartic protease (HAP) from Plasmodium falciparum. J. Mol. Biol. 2009, 388:520-540.
10. Bode W., Papamokos E., Musil D. The high-resolution X-ray crystal structure of the complex formed between subtilisin Carlsberg and eglin c, an elastase inhibitor from the leech Hirudo medicinalis. Structural analysis, subtilisin structure and interface geometry. Eur. J. Biochem. 1987, 166:673-692.
11. CCP4, 1994. Collaborative Computational Project, Number 4, 1994. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr. D50, 760-763.
12. Clemente J.C., Govindasamy L., Madabushi A., Fisher S.Z., Moose R.E., et al. Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Acta Crystallogr. 2006, D62:246-252.
13. Cohen G.E. ALIGN: a program to superimpose protein coordinates, accounting for insertions and deletions. J. Appl. Crystallogr. 1997, 30:1160-1161.
14. Coombs G.H., Goldberg D.E., Klemba M., Berry C., Kay J., Mottram J.C. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 2001, 17:532-537.
15. Davies D.R. The structure and function of the aspartic proteinases. Annu. Rev. Biophys. Biophys. Chem. 1990, 19:189-215.
16. DeLano W.L. The PyMOL Molecular Graphics System 2002, DeLano Scientific, San Carlos, CA.
17. Dunn B.M. Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem. Rev. 2002, 102:4431-4458.
18. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. 2004, D60:2126-2132.
19. Ersmark K., Samuelsson B., Hallberg A. Plasmepsins as potential targets for new antimalarial therapy. Med. Res. Rev. 2006, 26:626-666.
20. Francis S.E., Banerjee R., Goldberg D.E. Biosynthesis and maturation of the malaria aspartic hemoglobinases plasmepsins I and II. J. Biol. Chem. 1997, 272:14961-14968.
21. Francis S.E., Gluzman I.Y., Oksman A., Knickerbocker A., Mueller R., et al. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J. 1994, 13:306-317.
22. Gluzman I.Y., Francis S.E., Oksman A., Smith C.E., Duffin K.L., Goldberg D.E. Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. J. Clin. Invest. 1994, 93:1602-1608.
23. Greenwood B.M., Bojang K., Whitty C.J., Targett G.A. Malaria. Lancet 2005, 365:1487-1498.
24. Gutierrez-de-Teran H., Nervall M., Dunn B.M., Clemente J.C., Aqvist J. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor. FEBS Lett. 2006, 580:5910-5916.
25. Hill J., Tyas L., Phylip L.H., Kay J., Dunn B.M., Berry C. High level expression and characterisation of Plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Lett. 1994, 352:155-158.
26. Jaskolski M., Gilski M., Dauter Z., Wlodawer A. Stereochemical restraints revisited: how accurate are refinement targets and how much should protein structures be allowed to deviate from them?. Acta Crystallogr. 2007, D63:611-620.
27. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Cryst. 1993, 26:795-800.
28. Kimura T., Nguyen J.T., Maegawa H., Nishiyama K., Arii Y., et al. Chipping at large, potent human T-cell leukemia virus type 1 protease inhibitors to uncover smaller, equipotent inhibitors. Bioorg. Med. Chem. Lett. 2007, 17:3276-3280.
29. Kiriyama A., Mimoto T., Kiso Y., Takada K. Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations. Biopharm. Drug Dispos. 1993, 14:199-207.
30. Kiriyama A., Sugahara M., Yoshikawa Y., Kiso Y., Takada K. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs. Biopharm. Drug Dispos. 1996, 17:125-134.
31. Kiso A., Hidaka K., Kimura T., Hayashi Y., Nezami A., Freire E., Kiso Y. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II. J. Pept. Sci. 2004, 10:641-647.
32. Kiso Y. Kynostatin (KNI)-272 - a rationally designed tripeptide inhibitor of HIV protease. Nippon. Rinsho. 1993, 51(Suppl.):139-145.
33. Kiso Y. Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic. Adv. Exp. Med. Biol. 1995, 362:413-423.
34. Kiso Y. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Biopolymers 1996, 40:235-244.
35. Kiso Y., Matsumoto H., Mizumoto S., Kimura T., Fujiwara Y., Akaji K. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Biopolymers 1999, 51:59-68.
36. Koelsch G., Mares M., Metcalf P., Fusek M. Multiple functions of pro-parts of aspartic proteinase zymogens. FEBS Lett. 1994, 343:6-10.
37. Kolakovich K.A., Gluzman I.Y., Duffin K.L., Goldberg D.E. Generation of hemoglobin peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide transport in amino acid production. Mol. Biochem. Parasitol. 1997, 87:123-135.
38. Krissinel E., Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. 2004, D60:2256-2268.
39. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
40. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
41. LaVallie E.R., McCoy J.M. Gene fusion expression systems in Escherichia coli. Curr. Opin. Biotechnol. 1995, 6:501-506.
42. Liu P., Marzahn M.R., Robbins A.H., Gutierrez-de-Teran H., Rodriguez D., et al. Recombinant plasmepsin 1 from the human malaria parasite Plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis. Biochemistry 2009, 48:4086-4099.
43. Luker K.E., Francis S.E., Gluzman I.Y., Goldberg D.E. Kinetic analysis of plasmepsins I and II aspartic proteases of the Plasmodium falciparum digestive vacuole. Mol. Biochem. Parasitol. 1996, 79:71-78.
44. Luo Y., Pfuetzner R.A., Mosimann S., Paetzel M., Frey E.A., et al. Crystal structure of LexA: a conformational switch for regulation of self-cleavage. Cell 2001, 106:585-594.
45. Maegawa H., Kimura T., Arii Y., Matsui Y., Kasai S., Hayashi Y., Kiso Y. Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic. Bioorg. Med. Chem. Lett. 2004, 14:5925-5929.
46. Matthews B.W. Solvent content of protein crystals. J. Mol. Biol. 1968, 33:491-497.
47. Mimoto T., Imai J., Tanaka S., Hattori N., Kisanuki S., Akaji K., Kiso Y. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem. Pharm. Bull. (Tokyo) 1991, 39:3088-3090.
48. Moon R.P., Tyas L., Certa U., Rupp K., Bur D., et al. Expression and characterisation of plasmepsin I from Plasmodium falciparum. Eur. J. Biochem. 1997, 244:552-560.
49. Moura P.A., Dame J.B., Fidock D.A. Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors. Antimicrob. Agents Chemother. 2009, 53:4968-4978.
50. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. 1997, D53:240-255.
51. Nezami A., Kimura T., Hidaka K., Kiso A., Liu J., et al. High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 2003, 42:8459-8464.
52. Nguyen J.T., Hamada Y., Kimura T., Kiso Y. Design of potent aspartic protease inhibitors to treat various diseases. Arch. Pharm. (Weinheim) 2008, 341:523-535.
53. Nguyen J.T., Zhang M., Kumada H.O., Itami A., Nishiyama K., et al. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:366-370.
54. Prade L., Jones A.F., Boss C., Richard-Bildstein S., Meyer S., Binkert C., Bur D. X-ray structure of plasmepsin II complexed with a potent achiral inhibitor. J. Biol. Chem. 2005, 280:23837-23843.
55. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. 2001, D57:1373-1382.
56. Robbins A.H., Dunn B.M., Agbandje-McKenna M., McKenna R. Crystallographic evidence for noncoplanar catalytic aspartic acids in plasmepsin II resides in the Protein Data Bank. Acta Crystallogr. 2009, D65:294-296.
57. Sielecki A.R., Fedorov A.A., Boodhoo A., Andreeva N.S., James M.N. Molecular and crystal structures of monoclinic porcine pepsin refined at 1.8Å resolution. J. Mol. Biol. 1990, 214:143-170.
58. Silva A.M., Lee A.Y., Gulnik S.V., Maier P., Collins J., et al. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 1996, 93:10034-10039.
59. Tanaka T., Yada R.Y. Expression of soluble cloned porcine pepsinogen A in Escherichia coli. Biochem. J. 1996, 315(Pt. 2):443-446.
60. Umezawa H., Aoyagi T., Morishima H., Matsuzaki M., Hamada M. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J. Antibiot. (Tokyo) 1970, 23:259-262.
61. Wlodawer A., Minor W., Dauter Z., Jaskolski M. Protein crystallography for non-crystallographers or how to get the best (but not more) from the published macromolecular structures. FEBS J. 2008, 275:1-21.
62. Xiao H., Sinkovits A.F., Bryksa B.C., Ogawa M., Yada R.Y. Recombinant expression and partial characterization of an active soluble histo-aspartic protease from Plasmodium falciparum. Protein Expr. Purif. 2006, 49:88-94.
63. Xiao H., Tanaka T., Ogawa M., Yada R.Y. Expression and enzymatic characterization of the soluble recombinant plasmepsin I from Plasmodium falciparum. Protein Eng. Des. Sel. 2007, 20:625-633.
64. Zhang M., Nguyen J.T., Kumada H.O., Kimura T., Cheng M., Hayashi Y., Kiso Y. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme. Bioorg. Med. Chem. 2008, 16:6880-6890.
65. Zhang M., Nguyen J.T., Kumada H.O., Kimura T., Cheng M., Hayashi Y., Kiso Y. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties. Bioorg. Med. Chem. 2008, 16:5795-5802.